Alaunos Therapeutics Inc
TCRT
View Detailed Chart
2.420USD
-0.080-3.20%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
5.02MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-3.20%
5 Days
+4.76%
1 Month
+8.04%
6 Months
+68.06%
Year to Date
+27.03%
1 Year
-14.18%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. The Company is focused on exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. Separately, the Company is evaluating several potential in-licensing opportunities in obesity, oncology and virology.
Growing
The company is in a growing phase, with the latest annual income totaling USD 10.00K.
Overvalued
The company’s latest PE is 0.18, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 252.84K shares, decreasing 36.72% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 20.97K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.64.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. The Company is focused on exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. Separately, the Company is evaluating several potential in-licensing opportunities in obesity, oncology and virology.
Ticker SymbolTCRT
CompanyAlaunos Therapeutics Inc
CEOMr. Holger Weis, CPA
Websitehttps://alaunos.com/
Related Instruments
+0.68%
+1.38%
-2.48%
-1.57%
-0.75%
-0.09%
+1.34%
-1.77%
-0.67%
-3.03%
-0.85%
-0.87%
-0.50%
+0.44%
-0.19%
-1.18%
-2.84%
0.00%
+0.30%
-3.72%
